Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses [0.03%]
将酪氨酸激酶抑制剂介导的炎症与正常上皮细胞稳态和肿瘤治疗反应联系起来
Natalia J Gurule,Lynn E Heasley
Natalia J Gurule
Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor ...
Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations [0.03%]
具有p53突变的结直肠癌细胞中F10相对5-氟尿嘧啶活性增强
Anthony Dominijanni,William H Gmeiner
Anthony Dominijanni
Aim: Resistance to fluoropyrimidine drugs (FPs) is a major cause of mortality in colorectal cancer (CRC). We assessed the potency advantage of the polymeric FP F10 relative to 5-fluorouracil (5FU) in four human CRC cell l...